Tetravalent microprojection-based dengue chimeric virus vaccine raises potent neutralising antibodies in mice.

Jovin J Y Choo, Christopher L D McMillan, Connor A P Scott, Jessica J Harrison, Daniel Watterson, Roy A Hall, Paul R Young, Jody Hobson-Peters, David A Muller

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jovin J Y ChooSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.

Christopher L D McMillanSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.

Connor A P ScottSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.

Jessica J HarrisonSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.

Daniel WattersonSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.

Roy A HallSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.

Paul R YoungSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.

Jody Hobson-PetersSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.

David A MullerSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia. d.muller4@uq.edu.au.

Funding

National Health and Medical Research Council APP1139754National Health and Medical Research Council APP1178896

6 · The paper itself

Abstract

Dengue virus (DENV) is endemic throughout the tropical regions of the world. Due to the risk posed to the population living in dengue-endemic areas, the development of a dengue vaccine has been considered a high priority by the WHO for the past 50 years. The development of a new chimeric viral platform, based on the insect-specific orthoflavivirus, Binjari virus (BinJV) has facilitated the production of multiple orthoflavivirus vaccine candidates. This study describes the evaluation of four candidate chimeric dengue virus vaccines (BinJ/DENV-prME) delivered as either a monovalent or tetravalent vaccine formulations via an alternative delivery method, the high-density microarray patch (HD-MAP). These chimeric viruses elicited potent neutralising antibodies against both homologous and heterologous serotypes and were raised to equal levels, with no immunodominance observed for any serotype. When coupled with the HD-MAP, enhanced antibody kinetics were observed, resulting in higher levels of neutralising antibodies elicited following a single dose.

Identifiers

PMID41271772

DOI10.1038/s41541-025-01297-5

PMCPMC12638920

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.